Scleroderma Overview

Principles

Definition

Scleroderma is a concept within biomedical research and clinical science that refers to a group of chronic autoimmune diseases characterized by excessive collagen deposition and fibrosis in the skin and internal organs. This research area investigates the complex pathogenesis, diverse clinical manifestations, and therapeutic approaches associated with this condition, holding significant importance for understanding connective tissue disorders and systemic autoimmunity.

Ontological type

Pathogenesis Mechanisms

Therapeutic Strategies

Organ System Involvement

Key developments

Key Figures

Microvascular Histopathology Era era

Gerald P. Rodnan[1], active in scleroderma research during the Microvascular Histopathology Era, was associated with Washington University in St. Louis[3] and Columbia University[4]. His contributions include Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma[6], Progressive Systemic Sclerosis Sine Scleroderma[7], and Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma)[8], which collectively advanced the microvascular histopathology framework by linking dermal remodeling to disease phenotypes and severity. E. Carwile LeRoy[2], associated with Cornell University[5] and Columbia University[4] during this era, contributed to the vascular focus through work on endothelial pathology in scleroderma. Endothelial injury in scleroderma[9] highlighted microvascular involvement as an early and central feature, shaping diagnostic and prognostic approaches in systemic sclerosis for this era.

Integrated Vasculopathy-Fibrosis era

Thomas A. Medsger [1] is a leading figure in the Integrated Vasculopathy-Fibrosis era, associated with Johns Hopkins University [3] and University of Pennsylvania [4] during 1984–2008. His key contributions include the 2001 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis paper [7], the 2002 Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon paper [8], and the 1984 Physiologic Abnormalities of Cardiac Function in Progressive Systemic Sclerosis with Diffuse Scleroderma paper [9], which collectively refined disease classification, activity assessment, and recognition of organ-specific abnormalities—foundational steps for risk stratification and early intervention in this era. Thomas Krieg [2] is another leading figure associated with University of California, San Francisco [5] and Baylor College of Medicine [6] in this era. Krieg's contributions include the 2001 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis paper [7] and the 1988 Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization paper [10], which deepened insight into tissue remodeling and collagen biology, reinforcing the vasculopathy–fibrosis axis and guiding mechanistic targets for interventions in this era.

Precision Immunotherapy Era era

Richard M. Silver [1] is associated with Stanford University [3] and Johns Hopkins University [4] in the Precision Immunotherapy Era. His key contributions in this era include the 2013 Classification Criteria for Systemic Sclerosis [7], the Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial [8], and the EULAR recommendations for the treatment of systemic sclerosis [9], each advancing precision classification and standardized immunomodulatory strategies. Philip J. Clements [2] is affiliated with University of California, San Diego [5] and University of California, Los Angeles [6] during this period. Philip J. Clements [2] helped propagate the 2013 Classification Criteria for Systemic Sclerosis [7], contributed to the SLS II trial framework [8], and advanced EULAR EUSTAR treatment guidelines [9], essential for harmonizing multicenter outcomes and enabling precision immunotherapy approaches.